Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Critical Reviews in Oncology/Hematology
|
June 15, 2016
Review on TAS-102 development and its use for metastatic colorectal cancer
Jose Mauricio Mota, Leonardo G Fonseca, Maria Ignez Braghiroli, et al.
Prostate Cancer and Prostatic Diseases
|
May 1, 2019
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
Jose Mauricio Mota, Andrew J Armstrong, Steven M Larson, et al.
Oncotarget
|
November 29, 2017
A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Jose Mauricio Mota, Katharine Ann Collier, Ricardo Lima Barros Costa, et al.
Medicine
|
December 30, 2018
Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
Jose Mauricio Mota, Luana Guimarães Sousa, Maria Ignez Braghiroli, et al.
Journal of Hematology & Oncology
|
May 7, 2017
Wnt/beta-catenin pathway: modulating anticancer immune response
Sachin Gopalkrishna Pai, Benedito A Carneiro, Jose Mauricio Mota, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
European Urology Oncology
|
August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology
|
May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology
|
April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Bastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 20, 2019
Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma
Camila Kruschewsky Falcao, Marina Campos Simoes Cabral, Jose Mauricio Mota, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Critical Reviews in Oncology/Hematology
|
June 15, 2016
Review on TAS-102 development and its use for metastatic colorectal cancer
Jose Mauricio Mota, Leonardo G Fonseca, Maria Ignez Braghiroli, et al.
Prostate Cancer and Prostatic Diseases
|
May 1, 2019
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
Jose Mauricio Mota, Andrew J Armstrong, Steven M Larson, et al.
Oncotarget
|
November 29, 2017
A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Jose Mauricio Mota, Katharine Ann Collier, Ricardo Lima Barros Costa, et al.
Medicine
|
December 30, 2018
Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
Jose Mauricio Mota, Luana Guimarães Sousa, Maria Ignez Braghiroli, et al.
Journal of Hematology & Oncology
|
May 7, 2017
Wnt/beta-catenin pathway: modulating anticancer immune response
Sachin Gopalkrishna Pai, Benedito A Carneiro, Jose Mauricio Mota, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
European Urology Oncology
|
August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology
|
May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology
|
April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Bastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 20, 2019
Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma
Camila Kruschewsky Falcao, Marina Campos Simoes Cabral, Jose Mauricio Mota, et al.
Page
of 2